ITRMF ITERUM THERAPEUTICS PLC revenue, earnings and financials
For the quarter ended September 30, 2025, ITERUM THERAPEUTICS PLC reported revenue of $390K, net income of −$8.98M and diluted EPS of −$0.20; for the fiscal year ended December 2024 revenue was n/a.
ITRMF annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$18.7M, net income −$24.8M (margin n/a), EPS −$1.26
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$47.5M, net income −$38.4M (margin n/a), EPS −$2.96
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$30.4M, net income −$44.4M (margin n/a), EPS −$3.63
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$24.5M, net income −$91.6M (margin n/a), EPS −$8.41
ITRMF quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue $390K, net income −$8.98M, EPS −$0.20
- Quarter ended Jun 30, 2025: revenue n/a, net income −$6.51M, EPS −$0.16
- Quarter ended Mar 31, 2025: revenue n/a, net income −$4.89M, EPS −$0.14
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$6.58M, EPS −$0.20
- Quarter ended Sep 30, 2024: revenue n/a, net income −$6.09M, EPS −$0.30
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.00M, EPS −$0.30
- Quarter ended Mar 31, 2024: revenue n/a, net income −$7.10M, EPS −$0.46
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$12.4M, EPS −$0.93
- Quarter ended Sep 30, 2023: revenue n/a, net income −$3.88M, EPS −$0.30
- Quarter ended Jun 30, 2023: revenue n/a, net income −$12.2M, EPS −$0.95
- Quarter ended Mar 31, 2023: revenue n/a, net income −$9.89M, EPS −$0.78
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$5.09M, EPS −$0.41
- Quarter ended Sep 30, 2022: revenue n/a, net income −$29.1M, EPS −$2.38
- Quarter ended Jun 30, 2022: revenue n/a, net income −$6.74M, EPS −$0.55
- Quarter ended Mar 31, 2022: revenue n/a, net income −$3.50M, EPS −$0.29
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$4.18M, EPS −$7.92
- Quarter ended Sep 30, 2021: revenue n/a, net income $3.74M, EPS $0.28
- Quarter ended Jun 30, 2021: revenue n/a, net income $7.80M, EPS $0.04
- Quarter ended Mar 31, 2021: revenue n/a, net income −$98.9M, EPS −$0.81
ITRMF cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$26.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$39.3M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$18.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$15.8M, share buybacks n/a
ITRMF balance sheet
- Sep 30, 2025: cash $11.0M, total assets $32.5M, total liabilities $39.9M, shareholders' equity −$7.38M
- Jun 30, 2025: cash $13.0M, total assets $34.0M, total liabilities $37.9M, shareholders' equity −$3.89M
- Mar 31, 2025: cash $12.7M, total assets $33.0M, total liabilities $35.5M, shareholders' equity −$2.55M
- Dec 31, 2024: cash $24.1M, total assets $44.6M, total liabilities $48.7M, shareholders' equity −$4.08M
- Sep 30, 2024: cash $13.4M, total assets $15.9M, total liabilities $27.4M, shareholders' equity −$11.5M
- Jun 30, 2024: cash $4.98M, total assets $14.2M, total liabilities $25.1M, shareholders' equity −$10.9M
- Mar 31, 2024: cash $7.39M, total assets $19.6M, total liabilities $25.8M, shareholders' equity −$6.15M
- Dec 31, 2023: cash $6.07M, total assets $26.3M, total liabilities $32.7M, shareholders' equity −$6.40M, long-term debt $11.5M
Is ITRMF profitable?
No. ITERUM THERAPEUTICS PLC lost $27.0M over the last four quarters.
What is ITRMF's EPS?
Diluted earnings per share over the last four quarters were −$0.70; −$0.20 in the latest quarter.